Taxanes (e.g. docetaxel) have been used to as standard treatments for androgen-independent prostate cancer. However, many patients relapse due to the development of multiple drug resistance (MDR), which results in poor prognosis. To address this challenge, we propose to develop a polymeric nanomedicine which has integrated multiple innovations in drug discovery, cancer therapy and nanotechnology-based drug delivery. First, we will use a novel microtubule inhibitor, 4-substituted methoxybenzoyl-aryl-thiazole-100 (SMART), to overcome MDR in prostate cancers. Second, multifunctional polymer-drug conjugate (PDC) micelles will be utilized to targeted deliver SMART into prostate cancers. The unique design of PDC micelles enables prostate cancer specific drug delivery through both enhanced permeability and retention (EPR) effects and active tumor targeting via tumor targeting peptides. The central hypothesis is that tumor targeting pH-responsive polymer- drug conjugate (PDC) micelles can enhance the delivery of SMART drugs into prostate cancer cells and effectively treat MDR prostate cancers by inducing cell cycle arrest and apoptosis. The following specific aims will be investigated: (1) Synthesize pH-responsive Polymer-drug Conjugate Micelles for the Delivery of SMART;(2) Prepare Targeting Peptide Decorated PDC micelles for Prostate Cancer Targeting;(3) Evaluate Anticancer Effects of SMART PDC micelles with MDR Prostate Cancer cells.

Public Health Relevance

Prostate cancer is the second most common cancer affecting males in the USA. African American males, in particular, have the highest incidence for prostate cancer and are more likely to die of the disease than those of other ethnic populations in the United States. Despite a variety of current treatments, many patients relapse and develop resistant cancers. This research project will develop new polymeric nanomedicines to treat refractory prostate cancers, which, in the long term, can benefit late stage prostate cancer patients.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Continuance Award (SC3)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Krasnewich, Donna M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Hampton University
Schools of Pharmacy
United States
Zip Code
Chen, Yingzhi; Zhang, Meng; Min, Kyoung Ah et al. (2018) Improved Protein Toxin Delivery Based on ATTEMPTS Systems. Curr Drug Targets 19:380-392
Li, Feng; Mahato, Ram I (2017) Bioconjugate Therapeutics: Current Progress and Future Perspective. Mol Pharm 14:1321-1324
Irby, Danielle; Du, Chengan; Li, Feng (2017) Lipid-Drug Conjugate for Enhancing Drug Delivery. Mol Pharm 14:1325-1338
Chen, Yingzhi; Zhang, Meng; Jin, Hongyue et al. (2017) Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into prodrug-like feature. Biomaterials 116:57-68
Li, Feng; Snow-Davis, Candace; Du, Chengan et al. (2016) Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles. J Vis Exp :
Li, Feng; Mahato, Ram I (2015) miRNAs as targets for cancer treatment: therapeutics design and delivery. Preface. Adv Drug Deliv Rev 81:v-vi
Li, Feng; Mahato, Ram I (2014) MicroRNAs and drug resistance in prostate cancers. Mol Pharm 11:2539-52